Oct 6, 2026 06:57AM
Oct 6, 2026 05:37AM
Oct 5, 2026 07:00AM
Oct 5, 2026 07:00AM
Sep 29, 2026 09:41AM
Sep 25, 2026 04:16AM
Sep 24, 2026 04:05PM Rezolute Reports Fourth Quarter and Full Year Fiscal 2026 Financial Results and Provides Business Update
Sep 9, 2026 07:00AM
Sep 9, 2026 07:00AM
Jul 30, 2026 06:53AM
Jun 15, 2026 06:53AM
Jun 4, 2026 07:30AM
Jun 2, 2026 07:00AM
Jun 2, 2026 07:00AM Rezolute Announces Positive Interim Data for its Phase 3 upLIFT Study of Ersodetug in Tumor Hyperinsulinism
May 12, 2026 04:05PM
May 1, 2026 12:15PM
May 1, 2026 12:15PM
Mar 25, 2026 07:02AM
Mar 25, 2026 06:58AM
Mar 25, 2026 06:37AM
Mar 25, 2026 05:33AM Rezolute (RZLT) Reiterated at Market Perform by Citizens on CHI Program Clarity
Mar 24, 2026 03:40PM
Mar 24, 2026 07:00AM
Mar 24, 2026 07:00AM
Feb 12, 2026 04:05PM
Jan 8, 2026 04:13AM
Jan 7, 2026 07:00AM
Jan 7, 2026 07:00AM Rezolute Provides Insights from its Phase 3 sunRIZE Study in Congenital Hyperinsulinism and Shares Findings from its Expanded Access Program in Tumor Hyperinsulinism
Dec 12, 2025 06:43AM
Dec 11, 2025 07:00AM
Dec 11, 2025 07:00AM
Nov 6, 2025 04:05PM
Sep 18, 2025 05:27AM
Sep 17, 2025 04:05PM
Sep 3, 2025 06:49AM H.C. Wainwright Reiterates Buy Rating on Rezolute (RZLT)
Sep 2, 2025 07:30AM
Sep 2, 2025 07:30AM
May 28, 2025 02:27PM
May 28, 2025 08:02AM
May 28, 2025 08:00AM
May 13, 2025 04:05PM
May 5, 2025 08:02AM Rezolute (RZLT) Receives Breakthrough Therapy Designation from FDA for Ersodetug in the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism
May 5, 2025 08:00AM
Feb 12, 2025 04:05PM
Feb 5, 2025 06:40AM
Feb 4, 2025 08:00AM
Feb 4, 2025 08:00AM
Jan 7, 2025 08:02AM
Jan 7, 2025 08:00AM Rezolute Receives Breakthrough Therapy Designation from FDA for Ersodetug in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism
Dec 5, 2024 08:00AM

334,289 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All